Johan Jules Urbain van Hoof

Biotechnology Innovation Organization is the world's biotechnology organization, providing advocacy, business development and communications services for more than 1,200 members worldwide. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology technologies. Corporate members range from entrepreneurial companies developing a first product to Fortune 100 multinationals. also represent state and regional biotech associations, service providers to the industry and academic centers.

Tibotec-Virco NV develops drugs and individualized disease management products. The firm also offers early stage research programs concentrating on the development of treatments for cancer, hepatitis C, and other infectious diseases. The company also provides HIV drug resistance testing and other analytical services in the United States, Japan, Europe, Canada, and Australia. It has operations in Belgium, North Carolina, Ireland, and the United Kingdom. It was founded in by Paul Stoffels in March, 2001 and is headquartered in Mechelen, Belgium.

California Institute of Technology provides education focusing on science, engineering, academia, business, and public service. The company was founded in 1891 and it is headquartered in Pasadena, CA.

McLean Hospital, Inc. provides healthcare services. It offers specialized programs for the research and treatment of psychiatric and neurological illnesses, including: depression, bipolar and psychotic disorders, mood and anxiety disorders, substance abuse, geriatric mental illnesses and child adolescent psychiatric disorders. The company was founded in February, 1811 and is headquartered in Belmont, MA.

Memorial Sloan-Kettering Cancer Center operates as a private cancer center. It offers cancer care services to adult; and child and teen patients. Its services include risk assessment and screening; diagnosis and treatment; clinical trials; patient and caregiver education; and pediatric clinical trials. The company was founded by John J. Astor and Charlotte Astor in 1884 and is headquartered in New York, NY.

Johnson & Johnson Pharmaceutical Research & Development LLC provides research and development support services. It offers drug discovery and drug development in a variety of therapeutic areas, including CNS, Internal Medicine and Oncology, to address unmet medical needs worldwide. The company is headquartered in Raritan, NJ.

The Wistar Institute provides biomedical research services. It researches on diseases such as cancer, cardiovascular, autoimmune disorders and infectious diseases and develops vaccine. The company was founded in 1892 and is headquartered in Philadelphia, PA

The National Academies of Science operates as a private non-profit organization that provides advice in sciences, engineering and medicine. It conducted through seven major program areas: Behavioral and Social Sciences and Education, Earth and Life Studies, Engineering and Physical Sciences, Health and Medicine, Policy and Global Affairs, Transportation Research Board, and the Gulf Research Program. The company was founded on March 3, 1863 and is headquartered in Washington, DC.

Janssen Pharmaceutica NV engages in the development of medical solutions. It offers research and development services in the field of mental illness, neurological disorders, anesthesia, analgesia, gastrointestinal disorders, fungal infection, allergies and cancer. The firms products include Zytiga, Caelyx, Dacogen, Edurant, Fentanyl-Janssen, Intelence, Leustatin, , Pariet, and Reminyl. The company was founded in 1953 by Paul Janssen and is headquartered in Beerse, Belgium.

Covagen AG engages in the research in as well as development, production, and distribution of pharmaceutical and diagnostic products and technologies. The company was founded by Julian Bertschinger and Dragan Grabulovski in 2007 and is headquartered in Zug, Switzerland.

Part of Virco Manufacturing Corp., Virco, Inc. is a private company based in Torrance, CA.

Aragon Pharmaceuticals, Inc. develops biopharmaceutical products, It offers a pipeline of new anti-endocrine therapies targeting the biology of hormone resistant cancers. The company was founded by Charles L. Sawyers and Michael Jung on May 1, 2009 and is headquartered in San Diego, CA.

Interuniversitair Micro-Electronica Centrum VZW, also known as Imec, is a Belgian business accelerator. The non-profit company is based in Leuven, BE and has subsidiaries in the United States, Taiwan, India, Netherlands, and Belgium. Imec.istart is their main program, which helps startups grow and succeed. The Belgian company was founded in 1984 and has been led by CEO Luc van den Hove since then.

Philips Healthcare engages in the manufacture of electromedical apparatus. It develops products that offer added value to the entire care cycle: from disease prevention to screening, diagnosis, treatment and follow-up care at home or in hospital. It also deals with cardiology, oncology, and women's health. It focuses on serious health problems, which people are confronted, such as heart problems, lung and breast disease. The company is headquartered in Eindhoven, the Netherlands.

ARM is a Washington, DC-based multi-stakeholder advocacy organization that promotes global initiatives necessary to facilitate access to life-giving advances in regenerative medicine. The organization promotes legislative, regulatory reimbursement, investment, technical, and other initiatives to accelerate the development of safe and effective regenerative medicine technologies. ARM also works to increase public understand- ing of the field and its potential to transform human healthcare. Prior to the formation of ARM in 2009, there was a need for more coordinated and cohesive advocacy representing the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today ARM has more than 140 members and is the leading global advocacy organization in this field.

Vedanta Biosciences, Inc. develops microbial therapies that address the human immune system. It engages in the development of a new class of drugs that work by modulating the human microbiome, with an initial emphasis in autoimmune and inflammatory diseases. The company was founded by Ruslan Medzhitov, Alexander Rudensky, Brett Finlay, Kenya Honda, Dan Littman, Bernat Olle and David Steinberg in 2010 and is headquartered in Cambridge, MA.

NEXT Integrative Mind Life Sciences Ltd. provides personal and interpersonal performance

Part of Johnson & Johnson, Johnson & Johnson Innovation LLC focuses on accelerating innovation worldwide and forming collaborations between entrepreneurs and Johnson & Johnson's healthcare businesses. The private company is based in South San Francisco, CA. Johnson & Johnson Innovation provides scientists, entrepreneurs, and emerging companies with one-stop access to science and technology experts who can facilitate collaborations across the pharmaceutical, medical device, and consumer companies of Johnson & Johnson. The company connects with innovators through its regional innovation centers, Johnson & Johnson Innovation - JLABS, JJDC, Inc., and its business development teams to create customized deals and novel collaborations that speed up the development of innovations to solve unmet needs in patients. JLABS provides the laboratories, expertise, education, tools, and resources needed to help life science startups thrive, all with no strings attached. Johnson & Johnson Innovation Center for Device Innovation at the Texas Medical Center (CDI @ TMC) has been established to accelerate the development of medical devices.

Flare Therapeutics is a biotechnology company that focuses on drugging transcription factors to develop small molecule medicines. The company is based in Cambridge, MA. The company's integrated discovery engine converges genetic, biochemical, and chemical insights to reveal druggable pockets and identify small molecule ligands capable of modulating transcription factors of high therapeutic potential. Flare's proteomic and mass spectrometry platform is powered by a proprietary library of electrophilic compounds unique to the company. The team has rapidly established an emerging pipeline of programs, highlighted by FX-909, a first-in-class investigational orally bioavailable small molecule inhibitor of PPARG, a master regulator of the luminal lineage in advanced urothelial cancer that has entered the clinic. Flare Therapeutics was launched in 2021 and is backed by founding investor Third Rock Ventures, as well as Boxer Capital, Nextech Invest, Casdin Capital, Invus Financial Advisors, and Eventide Asset Management. The company was founded by Mitchell Lazar, Fraydoon Rastinejad, Robert J. Sims, and Steven L. McKnight. Amit Rakhit has been the CEO of the company since 2022.